Logo     Print Page  Close Window


SEC Filings


8-K
FIBROCELL SCIENCE, INC. filed this Form 8-K on 12/29/2017
Entire Document
 
 
Program Milestone Timing FCX-007 FDA grants Fast Track Designation January 2017 FCX-007 Phase 1/2 trial first adult patient dosed February 2017 FCX-007 DSMB recommendation (after 1 patient) May 2017 FCX-013 FDA grants Rare Pediatric Disease Designation June 2017 FCX-007 Phase 1/2 trial interim update September 2017 FCX-007 DSMB recommendation (after 3 patients) September 2017 FCX-007 Enrolled first adult patient in Phase 2 3Q2017 FCX-007 Additional dosing of Phase 1 adult patients 4Q2017 FCX-013 IND filing Early 1Q2018 FCX-007 Initiation of pediatric enrollment 1Q2018 FCX-013 Initiation of safety clinical trial 2018 Milestones and Financials 20 Category Amount Cash at September 30, 2017 $11.9M; closed $10.5M raise (gross) December 2017 Share Count (Outstanding/Fully Diluted) 25.9M/62.5M as of December 28, 2017 Cash Runway Cash into 1Q2019